Phase 2 N=32 A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
Chronic Hepatitis C
Primary: Adverse Event Profile of Repeated Dosing of CF102 — 6; 2; 2; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=6 A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
Fabry Disease
Primary: Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 — -3.31; -6.34 percent change
N/A N=17 Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents
Diabetes Mellitus, Type 1
Primary: Percent of Time Spent Near Normoglycemia — 43.4; 18.9; 45.1; 21.3 percentage time near normoglycemia
N/A N=70 Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection
Total Knee Arthroplasty
Primary: Pain Scores (Visual Analog Pain Scores) — 2.6; 3.3 units on a scale
Phase 3 N=226 EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
Breast Cancer · Neurotoxicity
Primary: The Level of Cognitive Dysfunction as Measured by the High Sensitivity Cognitive Screen (HSCS) Overall Score. — 12.2; 12.6; 3.9; 2.6 units on a scale*months — p=0.84
N/A N=132 Study of Self or Clinic Administration of DepoProvera
Contraception
Primary: Number of Participants Continuing DMPA at 6 Months — 61; 29 participants
Phase 3 N=347 A Study of AA4500 in Men With Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -34.4 percentage of curvature change
Phase 2 N=15 Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)
Autism Spectrum Disorder
Primary: Maximum Tolerated Dose (MTD) — 0.40 IU / kg
N/A N=32 Injection of Botox in the Perineal Muscles in Resistant Cases of Vaginal Spasm
Vaginismus
Primary: Success of Repeated Penetration of the Penis Through the Vaginal Introitus Into the Vagina Without or With Acceptable Pain — 28 participants
Phase 2 N=539 A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents
Meningitis, Meningococcal
Primary: Percentage of Participants With at Least 4-fold Rise in Recombinant Lipoprotein 2086 (rLP2086) Specific Serum Bactericidal Assay Using Human Complement (hSBA) Titer…
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
Phase 4 N=63 Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of CD27+ Switched Memory B Cells at Week 12 — 13.2; 13.8 Percentage of B Cells — p=0.3
Phase 2 N=18 Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy — 0.0 proportion with 6+ months PFS
N/A N=220 Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication
Pain, Postoperative
Primary: Postoperative Pain on a Visual Analogue Pain Scale at One Hour Postoperatively — 4.04; 5.09; 4.4 units on a scale
Phase 1 N=52 Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants
Bioavailability
Primary: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole on Day 1. — 1046.8846; 1164.3654 ng/mL